Back

Accro Bio doses first patient in Phase IIb ulcerative colitis trial of AC-101

Verifying
  • Accro Bioscience dosed the first patient in AC-101's Phase IIb ulcerative colitis trial.
  • Approximately 50 sites will test two AC-101 doses against placebo.
  • Accro Bio says Phase Ib results will be presented at UEG Week 2026.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.